-- Scott Roberts
TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine)
transdermal system has been approved by the U.S. Food and Drug
Administration to treat advanced Parkinson's disease and
moderate-to-severe restless leg syndrome, the Belgian drug maker
UCB said Tuesday in a news release.
The continuous drug delivery patch was first approved by the FDA
in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by
stimulating dopamine receptors within the caudate-putamen, the
portion of the brain that regulates movement, the company said.
In clinical testing, observed side effects of Neupro included
nausea, vomiting, skin site reactions, dizziness, insomnia and
Neupro contains sodium metabisulfite, which could cause deadly
allergic-like reactions in certain susceptible people. Also, the
drug should not be used by pregnant women, UCB warned.
To learn more about this medication, visit
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.